Thanks for your response. Of course European trials are required for European approval. It’s just odd that MSB are basically saying that a successful US Phase 3 trial result (hopefully due in the next few months) will still need to be supported by end data from a yet to be started European Ph3 trial to support initial regulatory application for the USA.
Ann: Grunenthal and MSB Enter Strategic Partnership for Back Pain, page-129
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
-0.020(2.12%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 93.0¢ | 93.5¢ | 92.0¢ | $2.103M | 2.270M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 106422 | 92.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.0¢ | 59027 | 3 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |